Your donation will make a difference:
Cystic Fibrosis Trust

UKCFC 2017: day two

'Clinical trials and increasing access for people with cystic fibrosis'

Thursday 7 September 2017

Buy tickets for day two

9.00 Registration and networking
10.00 Welcome to day two

David Ramsden, Chief Executive of the Cystic Fibrosis Trust


Session One

10.10 Clinical trials: Where are we now?

Chairman: Stuart Elborn, Professor of Respiratory Medicine

Imperial College London and the Royal Brompton Hospital

Introductory chair scene setting (five minutes) followed by three presentations.

10.15 What and why: clinical trials

Dr Alexander Horsley, Manchester Adult Cystic Fibrosis Centre (TBC) 

  • Some facts behind clinical trials
  • What is involved and why get involved?
10.30 Clinical Trials Accelerator Platform

Rebecca Brendell, Head of the Clinical Trials Accelerator Platform at the Cystic Fibrosis Trust

10.45 Forum: carer and people with cystic fibrosis perspectives

Zoe Elliott and other family representatives (tbc)

  • What is the experience of people who have taken part in clinical trials?
11.00 Coffee and networking (exhibition area)

Session Two

11.25 Clinical trials: what's coming down the line?

Chairman: Professor Stuart Elborn, Imperial College London and the Royal Brompton Hospital

11.30 Keynote: Future CF therapies are dependent on delivery of clinical trials

George Retsch-Bogart

University of North Carolina and Cystic Fibrosis Foundation Trials Development Network (tbc)

  • The role of the TDN in coordinating CF clinical trials in the USA
  • The increased number of trials in the next year
  • We need to find better outcome measures for trials that reflect patient need
12.10 The challenge to clinical trial design of personalised medicine

David Geller, Medical Director, CF

Dr Andrew Roberts, Novartis (TBC)

AbbVie (tbc)

  • The industry perspective of the bottleneck in clinical trials
  • Smarter ways of running clinical trials
12.25 The challenge of personalised/precision medicine in design of clinical trials
  • How can we move away from trials designed for large population outcome measures to ones where the numbers are small?
  • Adaptive design principles
  • Is this an opportunity to rethink clinical trials and identify ways of improving results and lowering costs?
13.00 Conference lunch (exhibition area)

Session Three

14.00 The Cystic Fibrosis Trust: 'a year in the life'

Meet the Trust: updates on the UK CF Registry, research, fundraising, policy and volunteering.


Session Four - Afternoon workshops

15.00 Multi-disciplinary interactive sessions

A. Clinical Psychologists (TBC) 

B. Nutrition (TBC)

C. Physiotherapists (TBC)

D. Pharmacists - UKCFPG (TBC)

E. CF Centre Directors Meeting (closed)

16.30 Close of conference

Research

The Trust is committed to funding and supporting cutting-edge research to find new and better treatments for cystic fibrosis. Take a look at some of that work and the progress that is being made.

Discover more

What is cystic fibrosis?

Find out more about cystic fibrosis, its diagnosis and how it is treated, as well as useful links to our publications and other organisations who can help.

Read on

More information

If you would like to find out more about any of our campaigns, publications or anything else, get in touch and we'll be happy to help.

Get in touch